載入...
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
The discovery of JAK2(V617F) a decade ago led to optimism for a rapidly developing treatment revolution in Ph(−) myeloproliferative neoplasms. Unlike BCR–ABL, however, JAK2 was found to have a more heterogeneous role in carcinogenesis. Therefore, for years, development of new therapies was slow, des...
Na minha lista:
| 發表在: | Onco Targets Ther |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4844455/ https://ncbi.nlm.nih.gov/pubmed/27143923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S83868 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|